Abstract
Singapore is one of the countries which has taken early, systematic, and rigorous nationwide responses to slowing the COVID-19 contagion down. By February 4, 2020, the government of Singapore restricted the mobility of the vulnerable age-groups. In the current study, we study the influence of the age-based vulnerability of the population with respect to COVID-19 conditions on the recovery of COVID-19 patients. We study 245 patients in Singapore recovered and discharged during January 23–April 01. We first study the descriptive statistics of the length of in-hospital stay (LOS) of the COVID-19 patients based on demographic variables, namely age, and gender. Then, we determine the distribution of LOS, using local and generalized linear regression models. We take the approach of periodization based on critical changes in the disease transmission model. Even though the overall recovery rate has reduced drastically after a sudden spike in daily confirmations, our analysis shows that there is a considerable shift in the COVID-19 confirmations to the population in the non-vulnerable age-groups. We show that the LOS of the non-vulnerable age group is considerably lower at 9 days, as opposed to 15 or 20 days in the existing literature.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been partially supported by the IBM Shared University Grant awarded to J. Sreevalsan-Nair and the Visvesvaraya Ph.D. Fellowship by the Ministry of Electronics and IT (MeitY), Government of India, awarded to R. R. Vangimalla.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used for this study is curated from the press releases published online by the Ministry of Health, Government of Singapore, and is available at https://github.com/vrrani/COVID19-Singapore
